CancerVax CEO David Hale to Present at UBS Warburg Global Life Sciences Conference; Presentation Will Be Webcast On CancerVax Web Site.Business Editors & Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 7, 2002 CancerVax Corporation announced today that President and Chief Executive Officer David Hale David Hale may refer to:
EST abbr. electroshock therapy ) during the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg Global Life Sciences Conference. The conference will take place October 7 - 10, 2002 at the Plaza Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . A webcast of the presentation will be available online through CancerVax's web site at www.cancervax.com and will be archived until November 10, 2002. About CancerVax Corporation (www.cancervax.com) CancerVax Corporation is a privately held biotechnology company focused on the research, development and commercialization of novel therapeutic cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine , angiogenesis inhibitors and monoclonal antibodies for the treatment and control of cancer. The Company's lead product candidate, CANVAXIN(TM), is a therapeutic cancer vaccine currently being evaluated in late stage clinical trials for the treatment of advanced-stage melanoma. CancerVax also plans to evaluate the CANVAXIN(TM) vaccine in the treatment of advanced-stage colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. . The Company has additional product candidates in pre-clinical development for the treatment of solid tumor cancers, including several monoclonal antibodies that appear to inhibit angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. , the blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. development that is necessary for tumor growth. CancerVax maintains its corporate headquarters in Carlsbad, California, and its biologics manufacturing facility in Los Angeles, California. CancerVax cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects Side effects Effects of a proposed project on other parts of the firm. or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CancerVax(R) and CANVAXIN(TM) are trademarks of CancerVax Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion